Clinical trials must represent those who will receive therapy
February 19, 2025Clinical trial participants tend to be healthier, younger and less diverse than the general population. That’s one likely reason that, after new drugs reach the market, outcomes in real-world patients often fall short of those seen in trials. In a commentary in AJMC - The American Journal of Managed Care's Evidence Based Oncology, Evolent senior advisor and chief medical officer emeritus, Dr. Andrew Hertler, reflects on recent findings that Black patients were seriously underrepresented in clinical trials for multiple myeloma therapies. He delves into the problem, explores how the industry might make trial populations more representative, and details Evolent’s efforts to consider clinical trials representation when developing pathways in oncology.